{Reference Type}: Journal Article
{Title}: Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption.
{Author}: Mdluli T;Slike BM;Curtis DJ;Shubin Z;Tran U;Li Y;Dussupt V;Mendez-Rivera L;Pinyakorn S;Stieh DJ;Tomaka FL;Schuitemaker H;Pau MG;Colby DJ;Kroon E;Sacdalan C;de Souza M;Phanupak N;Hsu DC;Ananworanich J;Ake JA;Trautmann L;Vasan S;Robb ML;Krebs SJ;Paquin-Proulx D;Rolland M;
{Journal}: Cell Rep
{Volume}: 43
{Issue}: 6
{Year}: 2024 Jun 25
暂无{DOI}: 10.1016/j.celrep.2024.114344
{Abstract}: A heterologous Ad26/MVA vaccine was given prior to an analytic treatment interruption (ATI) in people living with HIV-1 (mainly CRF01_AE) who initiated antiretroviral treatment (ART) during acute HIV-1. We investigate the impact of Ad26/MVA vaccination on antibody (Ab)-mediated immune responses and their effect on time to viral rebound. The vaccine mainly triggers vaccine-matched binding Abs while, upon viral rebound post ATI, infection-specific CRF01_AE binding Abs increase in all participants. Binding Abs are not associated with time to viral rebound. The Ad26/MVA mosaic vaccine profile consists of correlated non-CRF01_AE binding Ab and Fc effector features, with strong Ab-dependent cellular phagocytosis (ADCP) responses. CRF01_AE-specific ADCP responses (measured either prior to or post ATI) are significantly higher in individuals with delayed viral rebound. Our results suggest that vaccines eliciting cross-reactive responses with circulating viruses in a target population could be beneficial and that ADCP responses may play a role in viral control post treatment interruption.